21世纪经济报道记者 季媛媛近日,信达生物(01801.HK)宣布,其自主研发的GCG/GLP-1双受体激动剂玛仕度肽在Ⅲ期临床试验DREAMS-3中达成主要终点。有券商医药行业分析师对21世纪经济报道记者表示,近年来,国产GLP-1药物研发进入快车道,除信达生物外,包括恒瑞医药、华东医药、先为达生物、鸿运华宁、甘李药业等众多药企均在该领域积极布局。从靶点来看,单靶点GLP-1仍是主流,但双靶点(...
Source Link21世纪经济报道记者 季媛媛近日,信达生物(01801.HK)宣布,其自主研发的GCG/GLP-1双受体激动剂玛仕度肽在Ⅲ期临床试验DREAMS-3中达成主要终点。有券商医药行业分析师对21世纪经济报道记者表示,近年来,国产GLP-1药物研发进入快车道,除信达生物外,包括恒瑞医药、华东医药、先为达生物、鸿运华宁、甘李药业等众多药企均在该领域积极布局。从靶点来看,单靶点GLP-1仍是主流,但双靶点(...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.